Daniel Miotto Dupont
Daniel Miotto Dupont
Verified email at
Cited by
Cited by
Plasminogen activator inhibitor-1 and tumour growth, invasion, and metastasis
MKV Durand, JS Bødker, A Christensen, DM Dupont, M Hansen, ...
Thrombosis and haemostasis 91 (03), 438-449, 2004
Biochemical properties of plasminogen activator inhibitor-1
DM Dupont, JB Madsen, T Kristensen, JS Bodker, GE Blouse, T Wind, ...
Front Biosci 14, 1337-1361, 2009
Tumor‐Targeted Polydiacetylene Micelles for In Vivo Imaging and Drug Delivery
N Mackiewicz, E Gravel, A Garofalakis, J Ogier, J John, DM Dupont, ...
Small 7 (19), 2786-2792, 2011
Methods to identify aptamers against cell surface biomarkers
A Cibiel, DM Dupont, F Ducongé
Pharmaceuticals 4 (9), 1216-1235, 2011
Characterisation of aptamer–target interactions by branched selection and high-throughput sequencing of SELEX pools
DM Dupont, N Larsen, JK Jensen, PA Andreasen, J Kjems
Nucleic acids research 43 (21), e139-e139, 2015
Evidence for a pre-latent form of the serpin plasminogen activator inhibitor-1 with a detached β-strand 1C
DM Dupont, GE Blouse, M Hansen, L Mathiasen, S Kjelgaard, JK Jensen, ...
Journal of Biological Chemistry 281 (47), 36071-36081, 2006
Nucleic acid aptamers against proteases
D M Dupont, L M Andersen, K A Botkjaer, P A Andreasen
Current medicinal chemistry 18 (27), 4139-4151, 2011
In vivo validation of free-space fluorescence tomography using nuclear imaging
A Garofalakis, A Dubois, B Kuhnast, DM Dupont, I Janssens, ...
Optics letters 35 (18), 3024-3026, 2010
Mutational analysis of plasminogen activator inhibitor‐1
T Wind, JK Jensen, DM Dupont, P Kulig, PA Andreasen
European journal of biochemistry 270 (8), 1680-1688, 2003
RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1
JB Madsen, DM Dupont, TB Andersen, AF Nielsen, L Sang, DM Brix, ...
Biochemistry 49 (19), 4103-4115, 2010
Construction of a plasminogen activator inhibitor‐1 variant without measurable affinity to vitronectin but otherwise normal
JK Jensen, MKV Durand, S Skeldal, DM Dupont, JS Bødker, T Wind, ...
FEBS letters 556 (1-3), 175-179, 2004
Dissecting the effect of RNA aptamer binding on the dynamics of plasminogen activator inhibitor 1 using hydrogen/deuterium exchange mass spectrometry
MB Trelle, DM Dupont, JB Madsen, PA Andreasen, TJD Jørgensen
ACS chemical biology 9 (1), 174-182, 2013
Serum-stable RNA aptamers to urokinase-type plasminogen activator blocking receptor binding
DM Dupont, JB Madsen, RK Hartmann, B Tavitian, F Ducongé, J Kjems, ...
RNA 16 (12), 2360-2369, 2010
Interactions of plasminogen activator inhibitor-1 with vitronectin involve an extensive binding surface and induce mutual conformational rearrangements
GE Blouse, DM Dupont, CR Schar, JK Jensen, KH Minor, JY Anagli, ...
Biochemistry 48 (8), 1723-1735, 2009
A peptide accelerating the conversion of plasminogen activator inhibitor-1 to an inactive latent state
L Mathiasen, DM Dupont, A Christensen, GE Blouse, JK Jensen, A Gils, ...
Molecular pharmacology 74 (3), 641-653, 2008
A serum-stable RNA aptamer specific for SARS-CoV-2 neutralizes viral entry
J Valero, L Civit, DM Dupont, D Selnihhin, LS Reinert, M Idorn, BA Israels, ...
Proceedings of the National Academy of Sciences 118 (50), 2021
Nanopore sequencing of brain-derived full-length circRNAs reveals circRNA-specific exon usage, intron retention and microexons
K Rahimi, MT Venø, DM Dupont, J Kjems
Nature communications 12 (1), 1-15, 2021
Nanopore sequencing of full-length circRNAs in human and mouse brains reveals circRNA-specific exon usage and intron retention
K Rahimi, MT Venø, DM Dupont, J Kjems
BioRxiv, 567164, 2019
An albumin-oligonucleotide assembly for potential combinatorial drug delivery and half-life extension applications
M Kuhlmann, JBR Hamming, A Voldum, G Tsakiridou, MT Larsen, ...
Molecular Therapy-Nucleic Acids 9, 284-293, 2017
Expected and unexpected features of protein‐binding RNA aptamers
N Bjerregaard, PA Andreasen, DM Dupont
Wiley Interdisciplinary Reviews: RNA 7 (6), 744-757, 2016
The system can't perform the operation now. Try again later.
Articles 1–20